2023年5月18日

公司定位于促进发展新型钠离子通道(Naᵥ)抑制剂针对疼痛旧金山,2014年9月23日—SiteOne疗法公司今天宣布完成最初一轮股权融资。由西尔斯资本管理和Biobrit LLC与其他投资者资本和乔Zakrzewski使命湾,150万美元的资金头寸SiteOne推进其口服Naᵥ1.7抑制剂疼痛和进一步发展的技术平台长效局部止痛药,疼痛诊断和其他疼痛的迹象。结合融资,洛厄尔西尔斯(Sears资本管理)和乔Zakrzewski将加入SiteOne董事会。丹·布拉德伯里(BioBrit LLC)和道格·克劳福德(使命湾资本)将作为董事会观察员。“SiteOne技术平台有可能彻底改变治疗急性和慢性疼痛,”西尔斯说。”该公司独特的专有方法针对Naᵥ1.7,加上一个经验丰富的管理团队,一个很有吸引力的早期投资机会。“公司还宣布140万美元的奖,两年,二期SBIR格兰特SiteOne国立卫生研究院支持的项目开发选择性,口服抑制剂Naᵥ1.7作为急性和慢性疼痛的治疗。“融资和美国国立卫生研究院拨款代表SiteOne的重要里程碑,是一个价值的认可我们的技术平台,优化高选择性NaV抑制剂的痛苦,”斯坦·e·亚伯说,该公司的首席执行官。“我们很兴奋有一群投资者和美国国立卫生研究院支持公司,期待进一步发展我们的投资组合治疗的候选治疗急性和慢性疼痛。“SiteOne的主要程序是口服,Naᵥ1.7抑制剂治疗中度到重度的疼痛,代表一个潜在的更安全、更有效的治疗选项来代替口服阿片类止痛药。 Because of the growing problems of overuse and abuse of current oral opioid analgesics, there is a significant unmet medical need for an effective non-addictive treatment for pain. Naᵥ1.7 plays a critical role in the generation and conduction of pain signals and represents a potentially transformative approach to treating pain with non-opioid pain therapies. About SiteOne Therapeutics SiteOne Therapeutics, located in San Francisco, was founded with the goal of developing novel pain therapeutics and diagnostics to safely, effectively and efficiently treat acute and chronic pain without the limitations of existing pain therapies, such as NSAIDs or opioids. The company’s therapeutic candidates are highly selective sodium ion channel 1.7 (Naᵥ1.7) inhibitors based on naturally occurring small molecules. Given the critical role Naᵥ1.7 plays in the generation and conduction of pain signals, combined with the urgent need for new, non-opioid pain therapies, SiteOne is focused on advancing its lead product for the treatment of moderate to severe pain. Additional opportunities with the company’s technology include long-acting analgesics, PET imaging diagnostics for pain and other pain indications. SiteOne owns worldwide development and commercialization rights to its development programs through an exclusive license from Stanford University.